49
Participants
Start Date
February 1, 2017
Primary Completion Date
December 14, 2018
Study Completion Date
December 14, 2018
IgPro20
A liquid formulation of normal human IgG at a concentration of 20% administered as a subcutaneous infusion at a dose prescribed by subject's physician prior to study entry.
Icahn Medical Institute, New York
Long Island Jewish Medical Center, Great Neck
Center for Clinical Research Rochester General Hospital, Rochester
Duke University School of Medicine, Durham
Levine Children's Hospital, Charlotte
Georgia Pollens Clinical Research Centers, Albany
University of Southern Florida, St. Petersburg
Clinical Research Center of Alabama, Birmingham
Medical College of Wisconsin, Milwaukee
Research Solutions of Arizona, Litchfield Park
The Ottawa Hospital, Ottawa
McGill University, Montreal
Lead Sponsor
CSL Behring
INDUSTRY